UAE Health Ministry Clears Merck's Juvicor For Treating Type 2 Diabetes
This article was originally published in PharmAsia News
The United Arab Emirate's health ministry approved Merck's Juvicor (sitagliptin/saxagliptin) combination diabetes drug expected to be used to treat the 18% of the federation's population with the Type 2 form.
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.